Equilibrium Diagnostics
Equilibrium Diagnostics (Eqdx) offers a patented urine test that detects kidney tubular dysfunction earlier than conventional markers. The AP Reader analyzer measures urinary ammonium and pH with gold-standard precision, generating a uAPI score that reclassifies over 60% of CKD patients into more accurate risk categories. The test also supports research in cystic fibrosis and intestinal failure.
- Healthcare Technology
- Medical Devices
- Data & Analytics
- Hardware
- Artificial Intelligence
- Biotechnology
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Chronic kidney disease affects more than 800 million people worldwide, yet standard tests measuring glomerular filtration (eGFR) and albuminuria (UACR) often detect dysfunction only after significant, irreversible damage has occurred. Tubular function—which often deteriorates before glomerular damage—is overlooked, leaving clinicians without a full view of kidney health and causing many patients to progress to end-stage kidney disease that could have been delayed or prevented with earlier detection.
Solution
Equilibrium Diagnostics has developed the uAPI (urine Ammonium-pH Index), a patented diagnostic algorithm that uncovers tubular dysfunction from a single, routine urine sample. The company's AP Reader is an automated analyser that measures urinary ammonium and pH with gold-standard potentiometric precision, then converts raw measurements into a single, clinically meaningful score. This score provides actionable risk stratification, allowing clinicians to identify high-risk patients earlier and guide referrals, treatment, and monitoring decisions. In matched CKD Stage 3–4 patients, a low uAPI predicts a more than 7-fold higher risk of a serious kidney event, and adding uAPI to standard clinical variables reclassifies over 60% of patients into a more accurate risk category. The test is synergistic with existing measures, addressing the critical detection gap that limits the effectiveness of new therapies such as SGLT2 inhibitors that work best when started early.
Target Audience
Primary customers are clinical research laboratories and nephrology practices seeking earlier detection and better risk stratification for chronic kidney disease patients, as well as researchers studying acid-base balance, cystic fibrosis, and intestinal failure.
Features
- Direct measurement of urine pH, ammonium, titratable acidity, and bicarbonate from a standard urine sample
- Proprietary patented algorithm calculating the urine ammonium pH index (uAPI) as a single, clinically meaningful score
- AP Reader automated analyser with gold-standard potentiometric precision requiring no additional patient burden beyond a routine clinic urine sample
- Demonstrated ability to reclassify >60% of CKD patients into more accurate risk categories when added to standard clinical variables (age, sex, BMI, eGFR, uACR, diabetes status, systolic blood pressure)
- Utility beyond CKD, including assessment of CFTR modulator efficacy in cystic fibrosis and quantification of metabolic acid burden in intestinal failure patients
- Quantification of renal net acid concentration and evaluation of net endogenous acid production for dietary and metabolic research